Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.
Press releases published on June 26, 2025
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
GlobeNewswire
·
June 26, 2025
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on …
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
GlobeNewswire
·
June 26, 2025
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and …
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
GlobeNewswire
·
June 26, 2025
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study No evidence …
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
GlobeNewswire
·
June 26, 2025
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated …
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
GlobeNewswire
·
June 26, 2025
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to identify previously unknown proteins …
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
GlobeNewswire
·
June 26, 2025
Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE) In just six months, IM8 is one of the fastest growing supplement brands in the world, generating an extraordinary US$50m+ Annual Recurring Revenue IM8 …
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
GlobeNewswire
·
June 26, 2025
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under …
26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet
GlobeNewswire
·
June 26, 2025
MOORESVILLE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, America’s premier hemp and cannabinoid brand, introduces its largest THCA flower collection release with 26 indoor-grown unique strains handpicked for exceptional quality, flavor, and …
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
GlobeNewswire
·
June 26, 2025
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and …
Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne
GlobeNewswire
·
June 26, 2025
Saint-Herblain, France, le 26 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui un accord exclusif avec CSL Seqirus, l'une des plus grandes entreprises de vaccins antigrippaux au …
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
GlobeNewswire
·
June 26, 2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from …
Electronic Health Records (EHR) Market Valued at USD 33.45 Billion in 2024, Set to Grow at 4.59% CAGR Through 2032 | AnalystView Market Insights
GlobeNewswire
·
June 26, 2025
San Francisco, USA, June 25, 2025 (GLOBE NEWSWIRE) -- The Electronic Health Records (EHR) market was valued at USD 33,451.20 million in 2024 and is projected to grow at a CAGR of 4.59% from 2025 to 2032. This growth is driven by the global shift toward …